Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AHC.AX
Strong BuyFLAGAustco Healthcare Limited · Healthcare · Australia · $66M · Avg Vol: $27K/d
Austco Healthcare has strong quality Q73 and value V68, but momentum at M33 is well below the calibrated floor. A 22.0% forward-EPS cut is decisively adverse.
COMPANY DESCRIPTION
Austco Healthcare Limited manufactures and supplies advanced nurse call and clinical workflow solutions for hospitals, aged care facilities, and healthcare providers globally. The company maintains a strong competitive position through its proprietary Tacera software platform, which integrates clinical systems to improve operational efficiency. It is a globally active niche technology provider with a recurring revenue model driven by software licensing and maintenance contracts.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.9M | 42.0M | 58.2M | 81.4M | 31.4% | 93.0M | 93.7M | 100.0M | 10.8% |
| EPS (AUD) | 0.01 | 0.01 | 0.02 | 0.02 | 25.8% | 0.02 | 0.02 | 0.02 | 10.7% |
| Shares | 287.7M | 291.4M | 360.8M | 360.8M | +25.4% | 374.8M | — | — | — |
| Debt | 1.0M | 0.5M | 1.8M | 3.9M | 58.3% | 4.4M | — | — | — |
| Equity | 23.1M | 25.0M | 44.4M | 51.7M | 30.8% | — | — | — | — |
| Op CF | 1.9M | 0.3M | 11.3M | 13.4M | 90.4% | 20.4M | — | — | — |
| Inv CF | -1.6M | -1.6M | -11.1M | -12.3M | — | — | — | — | — |
| Fin CF | -0.3M | -1.6M | 8.8M | -0.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AHC.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AHC.AX | Austco Healthcare Limited(you) | $66M | 86 | Strong Buy |
| ANN.AX | Ansell Limited | $4.1B | 96 | Strong Buy |
| NAN.AX | Nanosonics Limited | $585M | 37 | Hold |
| VLS.AX | Vita Life Sciences Limited | $109M | 100 | Strong Buy |
| BLS.AX | BLS Pharmaceuticals Limited | $152M | 79 | Buy |
| CUVL | Clinuvel Pharmaceuticals Limited | $311M | 87 | Strong Buy |
| ATHE | Alterity Therapeutics Limited | $82M | 55 | Hold |
| ALC.AX | Alcidion Group Limited | $93M | 54 | Hold |
| CGS.AX | Cogstate Limited | $380M | 92 | Strong Buy |
| AVE.AX | Avecho Biotechnology Limited | $64M | 42 | Hold |
Peer medians: ROE -25.5% · P/E 35.3x · Gross margin 62.6%